What Protein Does Lipitor Bind to in the Body?
Lipitor (atorvastatin) primarily binds to HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway for cholesterol biosynthesis. This binding competitively inhibits the enzyme, reducing hepatic cholesterol production and increasing LDL receptor expression to lower circulating LDL cholesterol.[1]
How Does This Binding Work?
Atorvastatin's active acid form enters hepatocytes and reversibly binds HMG-CoA reductase at its active site, mimicking HMG-CoA substrate. This inhibition is dose-dependent, with IC50 around 5-10 nM, explaining its potency as a statin.[2]
Does Lipitor Bind to Plasma Proteins Too?
Yes, atorvastatin exhibits >98% binding to plasma proteins, mainly albumin (acid form) and alpha-1-acid glycoprotein (lactone form). This high binding limits free drug availability but does not affect its primary hepatic target.[1][3]
Why Does Protein Binding Matter for Lipitor Users?
High plasma protein binding means displacement by other drugs (e.g., via CYP3A4 interactions) can increase free atorvastatin levels, raising myopathy risk. Clinicians monitor this with drugs like cyclosporine or gemfibrozil.[4]
How Does Lipitor Compare to Other Statins' Binding?
| Statin | Primary Target Protein | Plasma Protein Binding |
|--------------|------------------------|------------------------|
| Atorvastatin | HMG-CoA reductase | >98% (albumin) |
| Simvastatin | HMG-CoA reductase | 95% (albumin) |
| Rosuvastatin | HMG-CoA reductase | 88% (albumin) |
| Pravastatin | HMG-CoA reductase | 50% (albumin) |[1][5]
Sources
[1]: Lipitor Prescribing Information (FDA)
[2]: DrugBank: Atorvastatin
[3]: PubMed: Atorvastatin Protein Binding
[4]: Clinical Pharmacology Review
[5]: DrugPatentWatch: Statin Comparisons